A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy

Vikram S. Kashyap, Alexander H. King, Mazin I. Foteh, Matthew Janko, Jeffrey Jim, Raghu L. Motaganahalli, Jeffrey Apple, Saideep Bose, Norman H. Kumins

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions. Methods: A retrospective review of all patients who underwent TCAR at four institutions between 2013 and 2017 was performed to evaluate the use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). TCAR patients had high-risk factors and were either enrolled in prospective trials or treated with a commercially available TCAR device after US Food and Drug Administration approval. Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were propensity matched in a 1:1 (CEA:TCAR) fashion with respect to preoperative comorbidities. Data were analyzed using statistical models with a P value of less than .05 considered significant. Individual and composite stroke, myocardial infarction, and death at 30 days and 1 year postoperatively were assessed. Results: Consecutive patients undergoing TCAR or CEA were identified (n = 663) and compared. Patients undergoing the TCAR procedure (n = 292) had higher rates of diabetes (P = .01), hyperlipidemia (P = .02), coronary artery disease (P < .01), and renal insufficiency (P < .01) compared with unmatched CEA patients (n = 371). Stroke rates were similar at 30 days (1.0% TCAR vs 1.1% CEA) and 1 year (2.8% TCAR vs 3.0% CEA) in the unmatched groups. After propensity matching by baseline characteristics including gender, age, symptom status (36.3%, 35.3%) and diabetes, 292 TCAR patients were compared with 292 CEA patients. TCAR patients were more likely to be treated preoperative and postoperatively with clopidogrel (preoperatively, 82.2% vs 39.4% [P < .01]; postoperatively, 98.3% vs 36.0% [P < .01]) and statins (preoperatively, 88.0% vs 75.0% [P < .01]; postoperatively, 97.8% vs 78.8% [P < .01]). Stroke (1.0% TCAR vs 0.3% CEA; P = .62) and death (0.3% TCAR vs 0.7% CEA; P = NS) rates were similar at 30 days and comparable at 1 year (stroke, 2.8% vs 2.2% [P = .79]; death 1.8% vs 4.5% [P = .09]). The composite end point of stroke/death/myocardial infarction at 1 month postoperatively was 2.1% vs 1.7% (P = NS). TCAR was associated with a decreased rate of cranial nerve injury (0.3% vs 3.8%; P = .01). Conclusions: These early data suggest that patients undergoing TCAR, even those with high-risk comorbidities, achieve broadly similar outcomes compared with patients undergoing CEA while mitigating cranial nerve injury. Further comparative studies are warranted.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalJournal of Vascular Surgery
Volume70
Issue number1
DOIs
StatePublished - Jul 1 2019

Fingerprint

Carotid Endarterectomy
Arteries
Stroke
Cranial Nerve Injuries
clopidogrel
Comorbidity
Cerebrovascular Circulation
Myocardial Infarction
Drug Approval
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Silk
Statistical Models
Femoral Artery
Hyperlipidemias

Keywords

  • Carotid revascularization
  • Carotid stenting
  • Stroke
  • TCAR

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Kashyap, V. S., King, A. H., Foteh, M. I., Janko, M., Jim, J., Motaganahalli, R. L., ... Kumins, N. H. (2019). A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy. Journal of Vascular Surgery, 70(1), 123-129. https://doi.org/10.1016/j.jvs.2018.09.060

A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy. / Kashyap, Vikram S.; King, Alexander H.; Foteh, Mazin I.; Janko, Matthew; Jim, Jeffrey; Motaganahalli, Raghu L.; Apple, Jeffrey; Bose, Saideep; Kumins, Norman H.

In: Journal of Vascular Surgery, Vol. 70, No. 1, 01.07.2019, p. 123-129.

Research output: Contribution to journalArticle

Kashyap, VS, King, AH, Foteh, MI, Janko, M, Jim, J, Motaganahalli, RL, Apple, J, Bose, S & Kumins, NH 2019, 'A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy', Journal of Vascular Surgery, vol. 70, no. 1, pp. 123-129. https://doi.org/10.1016/j.jvs.2018.09.060
Kashyap, Vikram S. ; King, Alexander H. ; Foteh, Mazin I. ; Janko, Matthew ; Jim, Jeffrey ; Motaganahalli, Raghu L. ; Apple, Jeffrey ; Bose, Saideep ; Kumins, Norman H. / A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy. In: Journal of Vascular Surgery. 2019 ; Vol. 70, No. 1. pp. 123-129.
@article{9fe8721f4f8d470db26de601f6c3bb5a,
title = "A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy",
abstract = "Objective: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions. Methods: A retrospective review of all patients who underwent TCAR at four institutions between 2013 and 2017 was performed to evaluate the use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). TCAR patients had high-risk factors and were either enrolled in prospective trials or treated with a commercially available TCAR device after US Food and Drug Administration approval. Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were propensity matched in a 1:1 (CEA:TCAR) fashion with respect to preoperative comorbidities. Data were analyzed using statistical models with a P value of less than .05 considered significant. Individual and composite stroke, myocardial infarction, and death at 30 days and 1 year postoperatively were assessed. Results: Consecutive patients undergoing TCAR or CEA were identified (n = 663) and compared. Patients undergoing the TCAR procedure (n = 292) had higher rates of diabetes (P = .01), hyperlipidemia (P = .02), coronary artery disease (P < .01), and renal insufficiency (P < .01) compared with unmatched CEA patients (n = 371). Stroke rates were similar at 30 days (1.0{\%} TCAR vs 1.1{\%} CEA) and 1 year (2.8{\%} TCAR vs 3.0{\%} CEA) in the unmatched groups. After propensity matching by baseline characteristics including gender, age, symptom status (36.3{\%}, 35.3{\%}) and diabetes, 292 TCAR patients were compared with 292 CEA patients. TCAR patients were more likely to be treated preoperative and postoperatively with clopidogrel (preoperatively, 82.2{\%} vs 39.4{\%} [P < .01]; postoperatively, 98.3{\%} vs 36.0{\%} [P < .01]) and statins (preoperatively, 88.0{\%} vs 75.0{\%} [P < .01]; postoperatively, 97.8{\%} vs 78.8{\%} [P < .01]). Stroke (1.0{\%} TCAR vs 0.3{\%} CEA; P = .62) and death (0.3{\%} TCAR vs 0.7{\%} CEA; P = NS) rates were similar at 30 days and comparable at 1 year (stroke, 2.8{\%} vs 2.2{\%} [P = .79]; death 1.8{\%} vs 4.5{\%} [P = .09]). The composite end point of stroke/death/myocardial infarction at 1 month postoperatively was 2.1{\%} vs 1.7{\%} (P = NS). TCAR was associated with a decreased rate of cranial nerve injury (0.3{\%} vs 3.8{\%}; P = .01). Conclusions: These early data suggest that patients undergoing TCAR, even those with high-risk comorbidities, achieve broadly similar outcomes compared with patients undergoing CEA while mitigating cranial nerve injury. Further comparative studies are warranted.",
keywords = "Carotid revascularization, Carotid stenting, Stroke, TCAR",
author = "Kashyap, {Vikram S.} and King, {Alexander H.} and Foteh, {Mazin I.} and Matthew Janko and Jeffrey Jim and Motaganahalli, {Raghu L.} and Jeffrey Apple and Saideep Bose and Kumins, {Norman H.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.jvs.2018.09.060",
language = "English (US)",
volume = "70",
pages = "123--129",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy

AU - Kashyap, Vikram S.

AU - King, Alexander H.

AU - Foteh, Mazin I.

AU - Janko, Matthew

AU - Jim, Jeffrey

AU - Motaganahalli, Raghu L.

AU - Apple, Jeffrey

AU - Bose, Saideep

AU - Kumins, Norman H.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Objective: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions. Methods: A retrospective review of all patients who underwent TCAR at four institutions between 2013 and 2017 was performed to evaluate the use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). TCAR patients had high-risk factors and were either enrolled in prospective trials or treated with a commercially available TCAR device after US Food and Drug Administration approval. Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were propensity matched in a 1:1 (CEA:TCAR) fashion with respect to preoperative comorbidities. Data were analyzed using statistical models with a P value of less than .05 considered significant. Individual and composite stroke, myocardial infarction, and death at 30 days and 1 year postoperatively were assessed. Results: Consecutive patients undergoing TCAR or CEA were identified (n = 663) and compared. Patients undergoing the TCAR procedure (n = 292) had higher rates of diabetes (P = .01), hyperlipidemia (P = .02), coronary artery disease (P < .01), and renal insufficiency (P < .01) compared with unmatched CEA patients (n = 371). Stroke rates were similar at 30 days (1.0% TCAR vs 1.1% CEA) and 1 year (2.8% TCAR vs 3.0% CEA) in the unmatched groups. After propensity matching by baseline characteristics including gender, age, symptom status (36.3%, 35.3%) and diabetes, 292 TCAR patients were compared with 292 CEA patients. TCAR patients were more likely to be treated preoperative and postoperatively with clopidogrel (preoperatively, 82.2% vs 39.4% [P < .01]; postoperatively, 98.3% vs 36.0% [P < .01]) and statins (preoperatively, 88.0% vs 75.0% [P < .01]; postoperatively, 97.8% vs 78.8% [P < .01]). Stroke (1.0% TCAR vs 0.3% CEA; P = .62) and death (0.3% TCAR vs 0.7% CEA; P = NS) rates were similar at 30 days and comparable at 1 year (stroke, 2.8% vs 2.2% [P = .79]; death 1.8% vs 4.5% [P = .09]). The composite end point of stroke/death/myocardial infarction at 1 month postoperatively was 2.1% vs 1.7% (P = NS). TCAR was associated with a decreased rate of cranial nerve injury (0.3% vs 3.8%; P = .01). Conclusions: These early data suggest that patients undergoing TCAR, even those with high-risk comorbidities, achieve broadly similar outcomes compared with patients undergoing CEA while mitigating cranial nerve injury. Further comparative studies are warranted.

AB - Objective: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions. Methods: A retrospective review of all patients who underwent TCAR at four institutions between 2013 and 2017 was performed to evaluate the use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). TCAR patients had high-risk factors and were either enrolled in prospective trials or treated with a commercially available TCAR device after US Food and Drug Administration approval. Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were propensity matched in a 1:1 (CEA:TCAR) fashion with respect to preoperative comorbidities. Data were analyzed using statistical models with a P value of less than .05 considered significant. Individual and composite stroke, myocardial infarction, and death at 30 days and 1 year postoperatively were assessed. Results: Consecutive patients undergoing TCAR or CEA were identified (n = 663) and compared. Patients undergoing the TCAR procedure (n = 292) had higher rates of diabetes (P = .01), hyperlipidemia (P = .02), coronary artery disease (P < .01), and renal insufficiency (P < .01) compared with unmatched CEA patients (n = 371). Stroke rates were similar at 30 days (1.0% TCAR vs 1.1% CEA) and 1 year (2.8% TCAR vs 3.0% CEA) in the unmatched groups. After propensity matching by baseline characteristics including gender, age, symptom status (36.3%, 35.3%) and diabetes, 292 TCAR patients were compared with 292 CEA patients. TCAR patients were more likely to be treated preoperative and postoperatively with clopidogrel (preoperatively, 82.2% vs 39.4% [P < .01]; postoperatively, 98.3% vs 36.0% [P < .01]) and statins (preoperatively, 88.0% vs 75.0% [P < .01]; postoperatively, 97.8% vs 78.8% [P < .01]). Stroke (1.0% TCAR vs 0.3% CEA; P = .62) and death (0.3% TCAR vs 0.7% CEA; P = NS) rates were similar at 30 days and comparable at 1 year (stroke, 2.8% vs 2.2% [P = .79]; death 1.8% vs 4.5% [P = .09]). The composite end point of stroke/death/myocardial infarction at 1 month postoperatively was 2.1% vs 1.7% (P = NS). TCAR was associated with a decreased rate of cranial nerve injury (0.3% vs 3.8%; P = .01). Conclusions: These early data suggest that patients undergoing TCAR, even those with high-risk comorbidities, achieve broadly similar outcomes compared with patients undergoing CEA while mitigating cranial nerve injury. Further comparative studies are warranted.

KW - Carotid revascularization

KW - Carotid stenting

KW - Stroke

KW - TCAR

UR - http://www.scopus.com/inward/record.url?scp=85059465545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059465545&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2018.09.060

DO - 10.1016/j.jvs.2018.09.060

M3 - Article

VL - 70

SP - 123

EP - 129

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 1

ER -